Women's Health
Wegovy for Women Over 40: Weight Loss, Hormones & Results
Quick Answer: Wegovy (semaglutide 7.2 mg) can be an effective weight loss treatment for women over 40, including those experiencing perimenopausal or menopausal weight changes. Clinical trial data shows average weight loss of approximately 21% of body weight over 72 weeks — results that are broadly consistent across age groups. Hormonal changes after 40 make weight loss harder through multiple mechanisms, and Wegovy's appetite-regulating action addresses several of these directly. Safety considerations specific to this age group, including bone density and cardiovascular risk, should be discussed with a prescribing clinician before starting.21%average weight loss at 72 weeks (STEP UP, 7.2 mg)
40s–60smost common age range for Wegovy patients
2×increased abdominal fat risk post-menopause
The Biology
Why Weight Loss Changes After 40 for Women
Many women over 40 describe a frustrating shift in their body — doing the same things they have always done but finding that weight accumulates more easily and responds less readily to diet and exercise. This is not imagined, and it is not simply about willpower or effort. The biological environment of the body changes substantially in the decade between 40 and 50, driven primarily by hormonal transitions but compounded by changes in metabolism, muscle mass and sleep.
Understanding these changes is clinically important because they directly inform why Wegovy may be particularly well-suited to women in this life stage — and why expecting the same results from approaches that worked at 30 is likely to lead to disappointment.
The Perimenopausal Transition
Perimenopause — the period of hormonal fluctuation that precedes the final menstrual period — typically begins between the ages of 40 and 45, though it can start earlier or later. During this phase, oestrogen and progesterone levels become erratic and progressively decline. This hormonal instability affects fat distribution, metabolic rate, sleep quality, mood and hunger regulation — all of which have direct consequences for body weight.
The perimenopausal transition can last anywhere from two to ten years before menopause is confirmed (defined as 12 consecutive months without a menstrual period). During this time, many women experience accelerating weight gain that feels disproportionate to any change in their behaviour — because in many cases it is. The underlying biology is changing faster than the lifestyle.
The Role of Oestrogen in Fat Distribution
Oestrogen plays a significant role in determining where the body preferentially stores fat. In premenopausal women, oestrogen promotes fat storage in the hips, thighs and buttocks. As oestrogen declines, fat redistribution occurs, with adipose tissue migrating progressively to the abdomen. This visceral fat — stored around internal organs — is metabolically active and is associated with higher risk of type 2 diabetes, cardiovascular disease and metabolic syndrome.
Research consistently shows that women gain an average of 1.5 to 2 kg per year during the menopausal transition, with a disproportionate increase in abdominal fat independent of total calorie intake. This shift occurs even in women who maintain stable body weight overall — their body composition is changing in a clinically meaningful way.
Hormones & Weight
Hormonal Changes That Affect Weight After 40
Weight management after 40 is complicated by the interaction of several hormonal systems undergoing change simultaneously. Understanding each hormone's role explains why this phase of life creates such a challenging environment for weight control — and why pharmacological support can make a meaningful difference.
Oestrogen
Regulates fat distribution, metabolism & insulin sensitivity
After 40: Declining levels drive visceral fat accumulation and reduce the body's insulin sensitivity, making calories more likely to be stored as fat. Wegovy connection: Appetite suppression reduces overall calorie intake, counteracting the increased energy-storage tendency driven by falling oestrogen.
Progesterone
Balances oestrogen, supports sleep & modulates appetite
After 40: Declining progesterone disrupts sleep quality and can increase appetite and cravings, particularly for high-carbohydrate comfort foods. Wegovy connection: Reduced appetite on Wegovy blunts progesterone-driven cravings, making dietary adherence significantly easier.
Cortisol
Primary stress hormone; influences fat storage
After 40: Disrupted sleep and the psychological demands of the menopausal transition elevate chronic cortisol, which promotes abdominal fat deposition. Wegovy connection: Weight loss on Wegovy has been associated with improvements in cortisol metabolism; reduced food preoccupation may also lower food-related stress.
Insulin
Regulates blood glucose uptake & fat storage
After 40: Increasing insulin resistance (compounded by declining oestrogen) means more insulin is required to manage blood glucose, promoting fat storage and making weight loss harder. Wegovy connection: Semaglutide improves insulin sensitivity and reduces post-meal glucose excursions, directly addressing one of the key metabolic barriers to weight loss in this age group.
Leptin & Ghrelin
Fullness signals & hunger drive
After 40: Hormonal shifts can blunt leptin signalling (reducing the fullness response) and amplify ghrelin (increasing hunger), creating a physiological drive toward overconsumption. Wegovy connection: Wegovy's GLP-1 receptor agonism works alongside leptin to reinforce satiety signals and reduce the hunger drive — directly addressing the disrupted appetite regulation of this life stage.
Metabolic Changes
How Metabolism Changes After 40
Metabolism — the rate at which the body burns energy at rest — is not fixed. It changes throughout life, and the decade between 40 and 50 typically brings a combination of factors that reduce metabolic rate and make the same calorie intake that maintained a stable weight at 30 gradually insufficient to prevent weight gain.
Muscle Mass Decline (Sarcopenia)
From approximately the age of 35, adults lose muscle mass at a rate of around 1% per year in the absence of resistance training. Muscle is metabolically active tissue — it burns calories even at rest. As muscle mass declines, resting metabolic rate (RMR) falls correspondingly. A woman who has lost 5 kg of lean muscle mass since her thirties may have a resting metabolic rate 100–150 kcal per day lower than it was then — enough to drive meaningful weight gain over time without any change in dietary behaviour.
This decline in muscle mass is compounded by declining physical activity and the fatigue associated with perimenopause, which often reduces the motivation and capacity for the resistance exercise that would otherwise preserve muscle.
Reduced Thermic Effect of Food
The thermic effect of food — the energy expended in digesting and metabolising meals — also declines with age and is influenced by both the composition of the diet and the metabolic efficiency of the body's digestive processes. Women over 40 who have shifted toward a higher proportion of ultra-processed foods (which are easier to digest and carry a lower thermic effect) may find this compounds the existing metabolic slowdown.
Sleep Disruption and Metabolic Rate
Sleep quality deteriorates significantly during perimenopause, driven by hot flushes, night sweats, anxiety and progesterone decline. Chronic sleep deprivation is independently associated with reduced metabolic rate, elevated cortisol, increased ghrelin and reduced leptin — effectively creating a hormonal environment that promotes weight gain regardless of dietary intake. This relationship between sleep disruption and metabolic health is one of the most important and frequently overlooked factors in weight management for women over 40.
Why diet alone becomes less effective after 40: The combination of declining muscle mass (reducing resting metabolic rate), increasing insulin resistance (promoting fat storage), disrupted appetite hormones (increasing hunger) and poor sleep (elevating stress hormones) creates a physiological environment in which the same dietary effort produces fewer results than it once did. This is not a failure of willpower — it is a biological reality that pharmacological support can meaningfully address.
How Wegovy Helps
How Wegovy Works for Women Over 40
Wegovy's mechanism of action — mimicking the GLP-1 hormone to reduce appetite, slow gastric emptying and influence central reward pathways associated with food — addresses several of the specific physiological challenges that women over 40 face.
Appetite Suppression in a High-Hunger Environment
For women experiencing the amplified hunger signals driven by declining progesterone, disrupted leptin signalling and elevated cortisol, appetite suppression represents perhaps the most clinically impactful aspect of Wegovy's effect. Patients frequently describe the relief of no longer being preoccupied with food — of having the option to make different choices because the physiological compulsion to eat has been substantially reduced, not just managed through willpower.
Improving Insulin Sensitivity
Semaglutide's beneficial effect on insulin sensitivity and glucose metabolism is well documented and is one of the reasons it was originally developed as a diabetes treatment. For women over 40 whose insulin resistance is increasing as oestrogen declines, this mechanism provides a direct metabolic benefit that supports weight loss and reduces the risk of progressing to type 2 diabetes.
Tackling Visceral Fat
Clinical trial data from the STEP programme demonstrates that weight loss on semaglutide includes a significant reduction in visceral adiposity — the dangerous abdominal fat that accumulates disproportionately after menopause. Waist circumference reductions of 10–14 cm were observed in STEP 1 participants. This is particularly meaningful for women over 40, for whom visceral fat accumulation is the primary driver of increased cardiovascular and metabolic risk.
The Psychological Dimension
Weight gain during perimenopause and menopause carries a significant psychological burden for many women, compounding the mood disruption, identity shifts and physical changes already associated with this life stage. Patients who achieve meaningful weight loss on Wegovy frequently describe improvements in mood, self-confidence and a sense of agency that extends beyond the physical results — effects that have real clinical significance for mental health and quality of life during a challenging life transition.
Expected Results
Expected Wegovy Results for Women Over 40
The STEP clinical trial programme did not conduct a dedicated subgroup analysis for women over 40, but the age distribution of participants — with the mean age in STEP 1 being 46 years and the majority of participants being women — means that the trial results are broadly representative of this demographic.
Women over 40 can expect broadly similar weight loss outcomes to those reported in the overall STEP UP trial population: average weight loss of approximately 19–21% of body weight over 72 weeks. Patients in perimenopause experiencing the most significant hormonal flux may find their weight loss trajectory is slightly less linear than trial averages suggest, with periods of plateau corresponding to hormonal shifts. This is normal and does not indicate treatment failure.
Non-Scale Results That Matter
For women over 40, the clinical benefits of Wegovy extend substantially beyond weight loss alone. Patients frequently report:
| Timepoint | Expected Weight Loss | Key Changes |
|---|---|---|
| Month 1–2 | 1–4 kg (1–4%) | Appetite reduction begins; energy levels may dip initially |
| Month 3 | 5–7% | Noticeable weight loss; clothing size may begin to change |
| Month 6 | ~10% | Significant visceral fat reduction; metabolic markers improving |
| Month 12 | ~14–15% | Full treatment effect; sustained weight loss with lifestyle support |
| 72 weeks (~18 months) | ~19–21% (at 7.2 mg) | Full treatment effect; ~84.5% of weight lost from body fat; muscle function preserved |
- Reduction in waist circumference and visible abdominal weight loss, even when overall scale loss is gradual
- Improved blood glucose control and reduced insulin resistance
- Lower blood pressure and improved cardiovascular risk markers
- Better sleep quality as weight decreases and night-time reflux and sleep apnoea symptoms improve
- Reduced joint pain in knees, hips and lower back
- Improved energy and stamina for daily activity and exercise
- Reduced food preoccupation and improved relationship with eating
Safety
Safety Considerations for Women Over 40
Wegovy is a prescription-only medicine that requires a clinical assessment before prescribing. For women over 40, several safety considerations deserve specific attention, both in the assessment process and throughout treatment.
| Consideration | Detail | Action Required |
|---|---|---|
| Bone density | Rapid weight loss can reduce bone mineral density; risk is higher post-menopause | Weight-bearing exercise and adequate calcium/vitamin D throughout treatment |
| HRT interaction | No known pharmacokinetic interaction between semaglutide and HRT generally — see oral progesterone note | Inform your prescribing clinician of all medications including HRT |
| Gallbladder risk | Weight loss — especially rapid loss — increases gallstone risk in women | Be aware of upper right abdominal pain; report to clinician promptly |
| Thyroid history | Wegovy is contraindicated in personal/family history of medullary thyroid carcinoma | Disclose full thyroid history before starting treatment |
| Cardiovascular risk | Women over 40 have increasing CVD risk; weight loss with Wegovy improves markers | Regular blood pressure and lipid monitoring recommended |
| Fertility | Weight loss can restore ovulation in women with anovulatory cycles | Use contraception if pregnancy is not desired; Wegovy is not recommended in pregnancy |
Before Starting Wegovy: Disclosures for Women Over 40
- Current HRT type and dosage (oestrogen-only or combined)
- History of thyroid conditions, particularly any nodules or family history of thyroid cancer
- Bone density history or risk factors for osteoporosis
- Current or planned contraceptive use
- History of gallbladder disease or gallstones
- Any history of eating disorders or disordered eating patterns
- Current mental health status and any relevant psychiatric history
Wegovy & Menopause
Wegovy and Menopause: Understanding the Connection
Menopause is not a disease, but its physiological consequences — particularly those related to metabolic health and body composition — create conditions in which pharmacological support for weight management may provide clinically meaningful benefit. Wegovy does not treat menopause itself, nor does it replace hormone replacement therapy (HRT) for women with significant menopausal symptoms. However, for women whose menopausal transition is associated with significant weight gain, the two interventions are not mutually exclusive.
Can Wegovy and HRT Be Taken Together?
Yes, however an important practical consideration applies to women taking oral progesterone tablets as part of their HRT regimen (such as Utrogestan, norethisterone, or medroxyprogesterone acetate). Because semaglutide slows gastric emptying, there is concern that it may reduce the absorption of oral progesterone, potentially leading to irregular bleeding and reduced protection of the womb lining — which over time could increase the risk of endometrial cancer. This concern does not apply to non-oral forms of progesterone delivery.
Women taking oral progesterone as part of their HRT should discuss their options with their prescribing clinician before starting Wegovy. Options may include:
Does HRT Help with Menopausal Weight Gain?
This is a question that comes up frequently in clinical practice. HRT does not cause significant weight loss in most women, but it may help to partially reverse the abdominal fat redistribution driven by declining oestrogen. Evidence suggests that transdermal oestrogen may have a marginally more favourable effect on abdominal fat distribution than oral oestrogen, though neither form produces meaningful weight loss as a primary effect. Women expecting HRT to resolve menopausal weight gain are likely to be disappointed; those hoping it will support body composition alongside other interventions may see modest additional benefit.
Menopausal Symptoms and Wegovy Results
The relationship between menopausal symptoms and Wegovy outcomes is bidirectional. Symptoms such as poor sleep, elevated stress and mood disruption can slow weight loss by perpetuating the hormonal environment that makes it harder. Conversely, as weight decreases on Wegovy, some menopausal symptoms — particularly joint pain, sleep apnoea and fatigue — often improve, creating a positive feedback loop that supports both weight loss and quality of life.
- Mirena coil (IUS) — considered the ideal option in most cases; provides progestogenic womb protection for up to 5 years and is also contraceptive
- Combined HRT patch — delivers both oestrogen and progestogen transdermally, bypassing the gut entirely
- Increased oral progesterone dose — a higher dose may be recommended for at least 4 weeks after starting or increasing Wegovy
- Vaginal progesterone — not formally licensed for this purpose but commonly used in practice
| Menopause Symptom | Link to Weight | How Wegovy May Help |
|---|---|---|
| Hot flushes and night sweats | Sleep disruption raises cortisol and hunger hormones, increasing calorie intake | Reduced appetite blunts the compensatory eating driven by poor sleep |
| Reduced oestrogen | Drives fat redistribution from hips/thighs to abdomen; reduces metabolic rate | Appetite suppression reduces calorie intake; weight loss partially reverses abdominal fat accumulation |
| Insulin resistance | Increasing insulin resistance promotes fat storage and makes weight loss harder | Semaglutide improves insulin sensitivity and reduces post-meal glucose spikes |
| Low mood and fatigue | Can reduce motivation for exercise and lead to comfort eating | Weight loss improves mood in many patients; reduced cravings lessen food-driven distress |
| Muscle loss (sarcopenia) | Reduced muscle mass lowers resting metabolic rate, making weight gain easier to accumulate | Weight loss on Wegovy should be accompanied by resistance exercise and adequate protein to preserve muscle |
| Joint pain | Excess weight compounds menopausal joint inflammation | Weight reduction reduces joint load; patients often report improved mobility and reduced discomfort |
Key Questions
Key Questions Answered
Is Wegovy effective for women over 40?
Yes. Clinical trial data from the STEP programme — in which the majority of participants were women with a mean age of 46 — demonstrates average weight loss of approximately 15% of body weight over 68 weeks on semaglutide 2.4 mg, and approximately 21% on semaglutide 7.2 mg in STEP UP. Women over 40 face specific physiological challenges to weight loss, including declining oestrogen, increasing insulin resistance, muscle mass loss and disrupted appetite hormones, and Wegovy's mechanism of action addresses several of these directly. Individual results will vary based on menopausal status, metabolic health, diet quality and adherence to treatment.
Why is weight loss harder after 40?
Weight loss becomes harder after 40 for women due to a convergence of hormonal and metabolic changes. Declining oestrogen drives fat redistribution from the hips and thighs to the abdomen, and reduces insulin sensitivity — making calories more likely to be stored as fat. Declining muscle mass lowers resting metabolic rate. Disrupted sleep from perimenopause elevates cortisol and hunger hormones. Changing progesterone levels increase appetite and cravings. Taken together, these changes mean that the same dietary effort and activity level that maintained weight at 30 is insufficient to prevent weight gain at 45 — through no fault of the individual.
Can hormones affect Wegovy results?
Yes, hormonal changes can influence the rate and pattern of weight loss on Wegovy, though they do not prevent the medication from working. Women in active perimenopause — where oestrogen and progesterone levels are fluctuating most significantly — may experience a less linear weight loss trajectory, with periods of plateau corresponding to hormonal shifts. Increasing insulin resistance can slow metabolic response in the early weeks. Disrupted sleep driven by hot flushes and night sweats can elevate cortisol and hunger hormones, partially counteracting appetite suppression. Managing these factors through sleep hygiene, stress reduction, adequate protein intake and, where appropriate, HRT alongside Wegovy can improve outcomes.
FAQs
Frequently Asked Questions: Wegovy for Women Over 40
Yes. The STEP trials enrolled a majority-female population with a mean age of 46 — making the data directly representative of this demographic. Average weight loss at 72 weeks on semaglutide 7.2 mg was approximately 21% of body weight in STEP UP. Wegovy's mechanism addresses several of the hormonal drivers of weight gain in this age group directly.
Yes. Perimenopause is not a contraindication to Wegovy. Women in the perimenopausal transition who meet the BMI eligibility criteria (BMI ≥30, or ≥27 with a weight-related comorbidity) may be prescribed Wegovy following clinical assessment. Hormonal fluctuation during perimenopause may affect the weight loss trajectory but does not prevent treatment from working.
For most HRT formulations, yes. However, women taking oral progesterone tablets (such as Utrogestan, norethisterone or medroxyprogesterone acetate) should discuss their options with their prescribing clinician before starting Wegovy, as semaglutide slows gastric emptying and may reduce oral progesterone absorption. Alternatives include the Mirena coil, a combined transdermal HRT patch, or increased oral progesterone dose. Women on oestrogen-only or non-oral progesterone HRT are not affected.
Weight loss on Wegovy includes a clinically significant reduction in visceral (abdominal) fat. STEP 1 trial participants experienced average waist circumference reductions of 10–14 cm. This is particularly meaningful for women over 40, given that visceral fat is the primary driver of elevated cardiovascular and metabolic risk in this group.
Rapid weight loss can reduce bone mineral density — a relevant consideration for post-menopausal women at increased osteoporosis risk. Adequate calcium and vitamin D intake and regular weight-bearing and resistance exercise throughout Wegovy treatment are strongly recommended to mitigate this risk.
Yes. Post-menopausal women who meet the clinical eligibility criteria may be prescribed Wegovy. The absence of active hormonal fluctuation in post-menopause often means the weight loss trajectory is more consistent and predictable than during active perimenopause.
Semaglutide does not directly regulate the menstrual cycle. However, weight loss itself can affect menstrual regularity — in women who are overweight or obese, weight loss often regularises cycles or restores ovulation where it had been disrupted. Women who are perimenopausal should be aware that weight loss may temporarily alter their cycle pattern.
Many women over 40 on Wegovy report improvements in energy levels as weight loss progresses. This is likely multifactorial — reduced body weight decreases physical load, improved sleep quality (as weight-related sleep apnoea and reflux improve) enhances daytime energy, and improved insulin sensitivity reduces the blood glucose fluctuations that contribute to afternoon fatigue.
There are no known significant interactions between semaglutide and commonly prescribed antidepressants. However, disclose all medications — including antidepressants, mood stabilisers and anxiolytics — to your prescribing clinician before starting Wegovy. Weight loss and appetite changes can sometimes affect mood, and ongoing monitoring is appropriate.
Post-menopausal women can expect a broadly similar weight loss timeline to the STEP trial averages: modest loss in the first four weeks, 5–7% by three months and 10% or more by six months. The absence of hormonal fluctuation that characterises active perimenopause means some women find their post-menopausal weight loss on Wegovy is more consistent than they might have expected.
Weight loss and reduced food preoccupation on Wegovy are associated with mood improvements in many patients. However, Wegovy is not an antidepressant and does not treat the neurological or mood symptoms of perimenopause directly. Women experiencing significant mood symptoms during the menopausal transition should discuss these with their GP, who may recommend HRT, psychological support or specific pharmacological treatment for mood.
Prioritising protein is the single most important dietary focus for women over 40 on Wegovy. A daily intake of at least 1.2 g of protein per kilogram of body weight helps preserve lean muscle mass during weight loss, supporting metabolic rate and body composition. Anti-inflammatory foods rich in omega-3 fatty acids, fibre and phytoestrogens may have additional benefits during the menopausal transition. Minimise ultra-processed foods, alcohol and high-sugar snacks.
Ready to Start Your Wegovy Journey?
GPhC-registered pharmacy (No. 9012585) · UK-licensed prescribers · Free online assessment · Superintendent Pharmacist: Palvinder Deol · Trustpilot 4.8 ★
Check Your Eligibility →
Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384:989–1002. | Wharton S et al. Once-weekly semaglutide 7.2 mg in adults with obesity (STEP UP). Lancet Diabetes Endocrinol. 2025;S2213–8587(25):00226–8. | Menopause. Nat Rev Dis Primers. 2015;1:15004. | Adiposity and the Menopause Transition. Maturitas. 2016;86:15–20. | Pathophysiology of human visceral obesity: an update. Physiol Rev. 2013;93(1):359–404. | NICE TA875. Semaglutide for managing overweight and obesity. March 2023. | MHRA. Wegovy prescribing information. 2023. | GPhC. Standards for registered pharmacies. 2023. gphc.org.uk | Happy Pharmacy (GPhC No. 9012585). Educational purposes only — not a substitute for individualised clinical assessment.